Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia

Author(s): L. Laurenti, L. De Padua, G. D'Arena, B. Vannata, I. Innocenti, M. Tarnani, S. Deaglio, S. Sica, D. G. Efremov and G. Leone

Volume 11 , Issue 6 , 2011

Page: [508 - 518] Pages: 11

DOI: 10.2174/138955711795843374

Price: $65

Abstract

Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.

Keywords: CD20, CD23, CD37, CD40, CD52, chronic lymphocytic leukemia, monoclonal antibodies, preclinical, CLL, alemtuzumab, rituximab, mAbs


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy